DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2008; 133(45): 2345-2348DOI: 10.1055/s-0028-1100926 Arzneimittel und Pharmakotherapie | Review articlePharmakologie, Onkologie© Georg Thieme Verlag KG Stuttgart · New YorkPosaconazol: Ein weiteres Triazol-Antimykotikum der neuen Generation?Posaconazole: Another triazole antifungal of the new generation?C. Müller1 , V. Kohl1 , F. Farowski2 , O. A. Cornely2 , 3 1Institut für Pharmakologie, Uniklinik Köln 2Klinik I für Innere Medizin, Uniklinik Köln 3Zentrum für Klinische Studien (BMBF 01KN0706), Klinikum der Universität zu Köln Recommend Article Abstract Buy Article(opens in new window) Schlüsselwörter Posaconazol - Triazolantimykotikum - Hämato-Onkologie - Lanosterol-14α-Demethylase - Cytochrom-P450-Enzyme - Pharmakokinetik - Arzneimittelinteraktionen Keywords Posaconazole - triazole antifungal drug - hemato-oncology - lanosterol-14α-demethylase - cytochrome-P450-enzyme - pharmacokinetics - drug-drug-interactions Full Text References Literatur 1 Aktories F. et al .Allgemeine und spezielle Pharmakologie und Toxikologie. München; Urban & Fischer 2005 2 Cornely O A. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356 348-359 3 Fachinformation zu Noxafil® SEB. 2007, Oktober 4 Hof H. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006; 49 Suppl 1 2-6 5 Keating G M. Posaconazole. Drugs. 2005; 65 1553-1567; discussion 1568 – 1559 6 Muller C. et al . HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses. 2006; 49 Suppl 1 17-22 7 Pitisuttithum P. et al . Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005; 56 745-755 8 Raad II. et al . Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42 1726-1734 9 Raad II. et al . Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008; 22 496-503 10 Smith J. et al . Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008; 30 167-172 11 Ullmann A J. et al . Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006; 50 658-666 12 Ullmann A J. et al . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356 335-347 13 Walsh T J. et al . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44 2-12 14 Wexler D. et al . Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004; 21 645-653 Dr. med. Carsten Müller Institut für Pharmakologie, Universität zu Köln Gleueler Str. 24 50931 Köln Phone: 0221/478-5066 Fax: 0221/478-7184 Email: c.mueller@uni-koeln.de